117 related articles for article (PubMed ID: 24220569)
1. Biomarkers in the management of breast cancer: great expectations, hard times.
Bertelli G; Nelmes DJ; Al-Allak A
Appl Immunohistochem Mol Morphol; 2013 Dec; 21(6):481-4. PubMed ID: 24220569
[TBL] [Abstract][Full Text] [Related]
2. Updated UK Recommendations for HER2 assessment in breast cancer.
Rakha EA; Pinder SE; Bartlett JM; Ibrahim M; Starczynski J; Carder PJ; Provenzano E; Hanby A; Hales S; Lee AH; Ellis IO;
J Clin Pathol; 2015 Feb; 68(2):93-9. PubMed ID: 25488926
[TBL] [Abstract][Full Text] [Related]
3. De novo resistance biomarkers to anti-HER2 therapies in HER2-positive breast cancer.
Madrid-Paredes A; Cañadas-Garre M; Sánchez-Pozo A; Calleja-Hernández MÁ
Pharmacogenomics; 2015; 16(12):1411-26. PubMed ID: 26257318
[TBL] [Abstract][Full Text] [Related]
4. The Evolving Landscape of HER2 Targeting in Breast Cancer.
Moasser MM; Krop IE
JAMA Oncol; 2015 Nov; 1(8):1154-61. PubMed ID: 26204261
[TBL] [Abstract][Full Text] [Related]
5. Detection of circulating tumor cells during follow-up of patients with early breast cancer: Clinical utility for monitoring of therapy efficacy.
Mikulová V; Cabiňaková M; Janatková I; Mestek O; Zima T; Tesařová P
Scand J Clin Lab Invest; 2014 Mar; 74(2):132-42. PubMed ID: 24350991
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of real-time immunohistochemistry and interaction map as an alternative objective assessment of HER2 expression in human breast cancer tissue.
Gedda L; Björkelund H; Lebel L; Asplund A; Dubois L; Wester K; Penagos N; Malmqvist M; Andersson K
Appl Immunohistochem Mol Morphol; 2013 Dec; 21(6):497-505. PubMed ID: 23455178
[TBL] [Abstract][Full Text] [Related]
7. Outcomes and recurrence patterns according to breast cancer subtypes in Korean women.
Lee Y; Kang E; Lee AS; Baek H; Kim EK; Park SY; Kim JH; Kim YJ; Kim SH; Kim IA; Eom KY; Kim SW
Breast Cancer Res Treat; 2015 May; 151(1):183-90. PubMed ID: 25893592
[TBL] [Abstract][Full Text] [Related]
8. Clinical implications of intratumoral heterogeneity of HER2 gene amplification in locally advanced HER2-positive breast cancer patients.
Hacioglu B; Akin S; Sever AR; Altundag K
Future Oncol; 2015 Sep; 11(18):2495-7. PubMed ID: 26278702
[No Abstract] [Full Text] [Related]
9. Breast cancer: updated guideline recommendations for HER2 testing.
Rakha EA; Ellis IO
Nat Rev Clin Oncol; 2014 Jan; 11(1):8-9. PubMed ID: 24322598
[TBL] [Abstract][Full Text] [Related]
10. Truly personalized therapy - an end to the era of one size fits all.
Harbeck N; Wuerstlein R
Nat Rev Clin Oncol; 2019 Feb; 16(2):77-78. PubMed ID: 30644455
[No Abstract] [Full Text] [Related]
11. [Beyond staging, typing and grading. New challenges in breast cancer pathology].
Kreipe HH; Ahrens P; Christgen M; Lehmann U; Länger F
Pathologe; 2010 Feb; 31(1):54-9. PubMed ID: 19949797
[TBL] [Abstract][Full Text] [Related]
12. Ki67 in breast cancer: a useful prognostic marker?
Caldarella A; Crocetti E; Paci E
Ann Oncol; 2014 Feb; 25(2):542. PubMed ID: 24412822
[No Abstract] [Full Text] [Related]
13. Predicting OncoDx recurrence scores with immunohistochemical markers.
Bradshaw SH; Pidutti D; Gravel DH; Song X; Marginean EC; Robertson SJ
Appl Immunohistochem Mol Morphol; 2013 Dec; 21(6):490-6. PubMed ID: 23455176
[TBL] [Abstract][Full Text] [Related]
14. Reply to Ki67 in breast cancer: a useful prognostic marker!
Denkert C; von Minckwitz G
Ann Oncol; 2014 Feb; 25(2):542-3. PubMed ID: 24431345
[No Abstract] [Full Text] [Related]
15. Advantages and disadvantages of technologies for HER2 testing in breast cancer specimens.
Furrer D; Sanschagrin F; Jacob S; Diorio C
Am J Clin Pathol; 2015 Nov; 144(5):686-703. PubMed ID: 26486732
[TBL] [Abstract][Full Text] [Related]
16. Preserved Axin expression is associated with an aggressive phenotype in invasive breast carcinomas.
Irini T; Paraskevi A; Ioanna G; Christos P; Lydia N
APMIS; 2013 Sep; 121(9):797-805. PubMed ID: 23278310
[TBL] [Abstract][Full Text] [Related]
17. [Are the new breast cancer subtypes (luminal A, B etc.) of practical impact? Yes].
Stöger H
Dtsch Med Wochenschr; 2013 Oct; 138(41):2096. PubMed ID: 24085364
[No Abstract] [Full Text] [Related]
18. Predictive markers in breast cancer: An update on ER and HER2 testing and reporting.
Calhoun BC; Collins LC
Semin Diagn Pathol; 2015 Sep; 32(5):362-9. PubMed ID: 25770732
[TBL] [Abstract][Full Text] [Related]
19. Poor prognosis of single hormone receptor- positive breast cancer: similar outcome as triple-negative breast cancer.
Bae SY; Kim S; Lee JH; Lee HC; Lee SK; Kil WH; Kim SW; Lee JE; Nam SJ
BMC Cancer; 2015 Mar; 15():138. PubMed ID: 25880075
[TBL] [Abstract][Full Text] [Related]
20. Prognostic value of phosphorylated HER2 in HER2-positive breast cancer patients treated with adjuvant trastuzumab.
Kurebayashi J; Kanomata N; Yamashita T; Shimo T; Mizutoh A; Moriya T; Sonoo H
Breast Cancer; 2015 May; 22(3):292-9. PubMed ID: 23749689
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
